×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
兰州大学 [11]
中国医学科学院 北京... [9]
合肥物质科学研究院 [8]
复旦大学上海医学院 [6]
厦门大学 [4]
上海药物研究所 [4]
更多...
内容类型
期刊论文 [53]
会议论文 [7]
学位论文 [1]
发表日期
2022 [1]
2021 [2]
2020 [2]
2019 [4]
2018 [10]
2017 [2]
更多...
学科主题
Biochemist... [2]
Oncology [2]
Science & ... [2]
Cardiovasc... [1]
Hematology [1]
Hematology... [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共61条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
期刊论文
PHARMACEUTICS, 2022, 卷号: 14
作者:
Liang, Huamin
;
Zou, Fengming
;
Fu, Liyi
;
Liu, Qingwang
;
Wang, Beilei
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
drug nanocrystal
stabilizer
micelle
BCR-ABL
chronic myeloid leukemia (CML)
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
期刊论文
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:
Lu, Tingting
;
Cao, Jiangyan
;
Zou, Fengming
;
Li, Xixiang
;
Wang, Aoli
收藏
  |  
浏览/下载:42/0
  |  
提交时间:2021/04/26
BCR-ABL
ABL mutants
Chronic myeloid leukemia
Kinase inhibitor
Imatinib resistance
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
期刊论文
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021
作者:
Wang, Zeng
;
Jiang, Liyu
;
Yan, Hao
;
Xu, Zhifei
;
Luo, Peihua
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2021/04/26
Adverse events
chronic myeloid leukemia
management
mechanisms
molecular target
nilotinib
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia
期刊论文
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020, 卷号: 29
作者:
Fu, Liyi
;
Zou, Fengming
;
Liu, Qingwang
;
Wang, Beilei
;
Wang, Junqing
收藏
  |  
浏览/下载:24/0
  |  
提交时间:2020/11/30
Chronic myeloid leukemia
BCR-ABL
Long-circulating nanoparticle
Drug delivery
Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
期刊论文
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2020, 卷号: 23, 期号: 4, 页码: 295-303
作者:
Lu, Jing
;
Zhang, YuHang
;
Wang, ShaoPeng
;
Bi, Yi
;
Huang, Tao
收藏
  |  
浏览/下载:35/0
  |  
提交时间:2020/07/01
Leukemia
protein-drug interactions
GO term
KEGG pathway
enrichment score
mRMR
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)
期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:
Wu, Jiaxin
;
Wang, Aoli
;
Li, Xixiang
;
Chen, Cheng
;
Qi, Ziping
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/11/27
BCR-ABL
PDGFR
chronic myeloid leukemia
kinase inhibitor
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade
期刊论文
CELLULAR SIGNALLING, 2019, 卷号: 63
作者:
Yin, Xiaolin
;
Zhou, Minran
;
Fu, Yue
;
Yang, Lin
;
Xu, Man
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2019/12/11
RBP2
Cell proliferation
CML
Crisis blast
BCR-ABL
PTEN
MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells
期刊论文
BIOMEDICINE & PHARMACOTHERAPY, 2019, 卷号: 112, 页码: 108623
作者:
Ma, Jichun[1]
;
Wu, Dehong[2]
;
Yi, Jing[3]
;
Yi, Yunyun[4]
;
Zhu, Xin[5]
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2019/12/24
MiR-378
K562 cell
Pluripotence
CML
Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety
期刊论文
2019, 卷号: 13, 期号: 3, 页码: 344-353
作者:
Huang, Xiaojun
;
Jiang, Qian
;
Hu, Jianda
;
Li, Jianyong
;
Jin, Jie
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2020/01/03
chronic myeloid leukemia (CML)
dasatinib
tyrosine kinase inhibitor
long-term follow-up
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 160, 页码: 61-81
作者:
Liu, Xuesong
;
Wang, Beilei
;
Chen, Cheng
;
Jiang, Zongru
;
Hu, Chen
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2019/01/11
ABL kinase
Kinase inhibitor
ABL mutant
CML
©版权所有 ©2017 CSpace - Powered by
CSpace